Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants

New oral anticoagulants (NOACs) is the preferred treatment in secondary prophylaxis of venous thromboembolic events (VTE). The aim of this study was to investigate possible risk factors associated with major bleeding in VTE-patients treated with NOACs. In this retrospective register-based study we s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallvik, Niklas, Renlund, Henrik, Själander, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282556/
https://www.ncbi.nlm.nih.gov/pubmed/33140837
http://dx.doi.org/10.1007/s11239-020-02319-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282556/
https://www.ncbi.nlm.nih.gov/pubmed/33140837
http://dx.doi.org/10.1007/s11239-020-02319-w

Ejemplares similares